Da-Som Kim, Eun Hye Kim, Ji Yong Kim, Dong Ha Kim, Yun Jung Choi, Jaeyi Jeong, Young Hoon Sung, Dong-Cheol Woo, Chong Jai Kim, Jae Cheol Lee, Miyong Yun, Jin-Yong Jeong, Jin Kyung Rho
Cancer Res Treat. 2026;58(1):115-127. Published online March 4, 2025
Purpose
Accumulating evidence has clarified that gut dysbiosis is involved in lung cancer development and progression. Although the relationship between tumors and gut microbiota has been extensively studied using clinical samples, no studies have examined the association between mutant epidermal growth factor receptor (EGFR)–induced lung carcinogenesis and dysbiosis in gut microbiota. Therefore, we investigated the gut microbiota profiles in stool samples from human lung-specific conditional EGFR-mutant transgenic mice during lung tumor carcinogenesis.
Materials and Methods
Stool samples were collected before tamoxifen treatment (V1) and at each time point following mutant EGFR expression in lung tissue (V2) and lung tumor appearance (V3). Fecal 16S rRNA taxonomy was analyzed to assess microbial diversity, composition, and dynamic changes at each time point.
Results
We found that microbiota richness and diversity were significantly elevated when tumors developed and grew in the lung. Phylogenetic analysis of the microbial community revealed that Lachnospiraceae, Ruminococcaceae, Porphyromonadaceae, Rhodospirillaceae, Odoribacteraceae, and Desulfovibrionaceae showed a significant increase at the V3 stage compared to the V1 stage at the family level. In contrast, Lactobacillaceae, Bacteroidaceae, Muribaculaceae, Coriobacteriaceae, and Rikenellaceae significantly decreased at the V3 stage compared to the V1 stage. Furthermore, Lactobacillus species, also known as short chain fatty acid-producing bacteria, were relatively abundant at the V1 stage but were depleted with the occurrence of lung tumors at the V3 stage.
Conclusion
Changes in gut microbiota, such as Lactobacillus species, may be a predictive factor for the emergence and progression of tumors in an animal model of lung adenocarcinoma induced by mutant EGFR.
Citations
Citations to this article as recorded by
Microbiome and
EGFR
-mutant non-small cell lung cancer: a complex interplay
Serena Eccher, Marco Sposito, Ilaria Mariangela Scaglione, Luca Pasqualin, Michele Rota, Adele Bonato, Lucia Longo, Alice Avancini, Ilaria Trestini, Daniela Tregnago, Jessica Insolda, Michele Milella, Sara Pilotto, Lorenzo Belluomini Expert Review of Clinical Immunology.2026; 22(3): 295. CrossRef
Hericium erinaceus Extracts Exert Gastroprotective Effects Through Modulation of the Gut Microbiota and Metabolites Ruixin Bei, Lifan Yu, Zhonghua Lu, Tingxuan Zong, Yanfang Sun Food Science & Nutrition.2026;[Epub] CrossRef
Gut microbiota and metabolites: emerging prospects in the treatment of non-small cell lung cancer Jing-Mian Jiao, Chen-Guang Liu, Dan Zang, Jun Chen Frontiers in Immunology.2025;[Epub] CrossRef
Study on the Impact of Changes in Intestinal Microbiota Structure of Lung Cancer Patients on the Efficacy of Immune Checkpoint Inhibitors 静 鲁 Advances in Clinical Medicine.2025; 15(11): 744. CrossRef
Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi
Cancer Res Treat. 2022;54(4):1005-1016. Published online December 3, 2021
Purpose The aim of this study is to evaluate the safety and efficacy of ex vivo activated and expanded natural killer (NK) cell therapy (SNK01) plus pembrolizumab in a randomized phase I/IIa clinical trial.
Materials and Methods Overall, 18 patients with advanced non–small cell lung cancer (NSCLC) and a programmed death ligand 1 tumor proportion score of 1% or greater who had a history of failed frontline platinum-based therapy were randomized (2:1) to receive pembrolizumab every 3 weeks +/– 6 weekly infusions of SNK01 at either 2×109 or 4×109 cells per infusion (pembrolizumab monotherapy vs. SNK01 combination). The primary endpoint was safety, whereas the secondary endpoints were the objective response rate (ORR), progression-free survival (PFS), overall survival, and quality of life.
Results Since no dose-limiting toxicity was observed, the maximum tolerated dose was determined as SNK01 4×109 cells/dose. The safety data did not show any new safety signals when SNK01 was combined with pembrolizumab. The ORR and the 1-year survival rate in the NK combination group were higher than those in patients who underwent pembrolizumab monotherapy (ORR, 41.7% vs. 0%; 1-year survival rate, 66.7% vs. 50.0%). Furthermore, the median PFS was higher in the SNK01 combination group (6.2 months vs. 1.6 months, p=0.001).
Conclusion Based on the findings of this study, the NK cell combination therapy may consider as a safe treatment method for stage IV NSCLC patients who had a history of failed platinum-based therapy without an increase in adverse events.
Citations
Citations to this article as recorded by
Cell therapy in sarcoma: current landscape and future directions Taha Koray Sahin, Theodora Germetaki, Deniz Can Guven, Serkan Akin, Omer Dizdar, Fiona Thistlethwaite, Elizabeth A Connolly, Kok Haw Jonathan Lim Journal for ImmunoTherapy of Cancer.2026; 14(1): e013396. CrossRef
NK cell infusion is well-tolerated and shows preliminary efficacy in patients with recurrent hepatocellular carcinoma post-liver transplantation : a phase I trial Fan Yang, Yihang Gong, Xiaofang Zheng, Beibei Ni, Jianxi Lu, Xiaoyan Chen, Jintao Cheng, Panlong Li, Cong Du, Yunhao Chen, Yingcai Zhang, Shuhong Yi, Guoying Wang, Qi Zhang, Yang Yang, Wenjie Chen Journal of Translational Medicine.2026;[Epub] CrossRef
Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review Lucie Biard, Vincent Lévy, Sylvie Chevret, Annette Künkele, Stefanie Grunwald, Alessandro Aiuti, Bjarne Kuno Møller, Reno Debets, Stephan Mielke, Johan van Eldere, Antonia Müller, Silvia Martin Lluesma, Lorena Consolino, Matt Bolz-Johnson, Stefano Benvenu Molecular Therapy Advances.2026; 34(1): 201651. CrossRef
Cellular Therapies in Solid Tumors: Are We Ready for Primetime? Giuseppe Maiocco, Vinicius Ernani, Michael P. Gustafson, Salman R. Punekar, Konstantinos Leventakos, Julian Molina, Yousef Zakharia, Mitesh Borad, Antonious Z. Hazim JCO Oncology Practice.2026;[Epub] CrossRef
Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study Clemente Humberto Zúñiga, Blanca Isaura Acosta, Rufino Menchaca, Cesar A. Amescua, Sean Hong, Lucia Hui, Minchan Gil, Yong-hee Rhee, Sangwook Yoon, Minji Kim, Paul Y. Chang, Yong Man Kim, Paul Y. Song, Katia Betito Alzheimer's Research & Therapy.2025;[Epub] CrossRef
Adopting tomorrow’s therapies today: a perspective review of adoptive cell therapy in lung cancer Faith Abodunrin, Daniel J Olson, Oluwatosin Emehinola, Christine M Bestvina Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef
Preclinical investigation of anti-tumor efficacy of allogeneic natural killer cells combined with cetuximab for head and neck squamous cell carcinoma Chaeyeon Kim, Mina Han, Gamin Kim, Wonrak Son, Jeongah Kim, Minchan Gil, Yong-Hee Rhee, Nam Suk Sim, Chang Gon Kim, Hye Ryun Kim Cancer Immunology, Immunotherapy.2025;[Epub] CrossRef
Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy Tesfahun Dessale Admasu, John S. Yu Aging Cell.2025;[Epub] CrossRef
Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy Bryan Marr, Donghyeon Jo, Mihue Jang, Seung-Hwan Lee Immune Network.2025;[Epub] CrossRef
The updated network meta-analysis of the therapeutic efficacies of lung cancer: A systematic review and meta-analysis Chuan-Hsin Chang, Chih-Cheng Chien, Yue-Cune Chang Tzu Chi Medical Journal.2025; 37(3): 339. CrossRef
Synergistic Anti-Tumor Efficacy of Modified FOLFIRINOX and NK Cell Therapy in Pancreatic Ductal Adenocarcinoma Hye-Seong Park, Jun Eul Hwang, Je-Jung Lee, Woo Kyun Bae Cancers.2025; 17(17): 2785. CrossRef
Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers Jie Ma, Jingjing Yue, Yangyang Li, Yutong Li, Hongbo Dong, Fang Fang, Weihua Xiao Cellular Oncology.2025; 48(6): 1837. CrossRef
Efficacy and safety of natural killer cell therapy for the treatment of advanced non-small cell lung cancer: A meta-analysis and systematic review Zhengnan Li, Xiu’e Wang, Shaoqing Chen, Ping Zhang, Xiujuan Wang, Xinye Ni, Chunlin Mou Immunologic Research.2025;[Epub] CrossRef
Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical st Myeong Geun Choi, Gun Woo Son, Mi Young Choi, Jae Seob Jung, Jin Kyung Rho, Wonjun Ji, Byeong Gon Yoon, Jong-Min Jo, Yong Man Kim, Dae-Hyun Ko, Jae Cheol Lee, Chang-Min Choi Journal for ImmunoTherapy of Cancer.2024; 12(3): e008585. CrossRef
Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells Jaya Lakshmi Thangaraj, Michael Coffey, Edith Lopez, Dan S. Kaufman Cell Stem Cell.2024; 31(9): 1327. CrossRef
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy Xin Su, Jian Li, Xiao Xu, Youbao Ye, Cailiu Wang, Guanglong Pang, Wenxiu Liu, Ang Liu, Changchun Zhao, Xiangyong Hao Journal of Translational Medicine.2024;[Epub] CrossRef
Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment Raj Kumar, Romi Gupta Frontiers in Oncology.2024;[Epub] CrossRef
Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis Heesook Park, Gyurin Kim, Najin Kim, Sungyoen Ha, Hyeonwoo Yim Frontiers in Immunology.2024;[Epub] CrossRef
Next-generation immunotherapy: igniting new hope for lung cancer Molly S. C. Li, Andrew L. S. Chan, Kevin K. S. Mok, Landon L. Chan, Tony S. K. Mok Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Engineered Cellular Therapies for the Treatment of Thoracic Cancers Spencer M. Erickson, Benjamin M. Manning, Akhilesh Kumar, Manish R. Patel Cancers.2024; 17(1): 35. CrossRef
Cellular Therapy in NSCLC: Between Myth and Reality Martina Imbimbo, Laureline Wetterwald, Alex Friedlaender, Kaushal Parikh, Alfredo Addeo Current Oncology Reports.2023; 25(10): 1161. CrossRef
NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors Sara Witting Christensen Wen, Line Nederby, Rikke Fredslund Andersen, Torben Schjødt Hansen, Christa Haugaard Nyhus, Ole Hilberg, Anders Jakobsen, Torben Frøstrup Hansen British Journal of Cancer.2023; 129(1): 135. CrossRef
Harnessing Natural Killer Cells for Lung Cancer Therapy Shoubao Ma, Michael A. Caligiuri, Jianhua Yu Cancer Research.2023; 83(20): 3327. CrossRef
Natural killer cells: the next wave in cancer immunotherapy Xin Chen, Lei Jiang, Xuesong Liu Frontiers in Immunology.2022;[Epub] CrossRef